[1] Scholmerich, J. (2003): Inflammatory bowel disease, Endoscopy 35 [2], Seite 164-170. URL: PM:12561010

[2] Timmer, A. und Goebell, H. (1999): Incidence of ulcerative colitis, 1980-1995--a prospective study in an urban population in Germany, Z.Gastroenterol. 37 [11], Seite 1079-1084. URL: PM:10604221

[3] Timmer, A.; Breuer-Katschinski, B. und Goebell, H. (1999): Time trends in the incidence and disease location of Crohn's disease 1980-1995: a prospective analysis in an urban population in Germany, Inflamm.Bowel.Dis. 5 [2], Seite 79-84. URL: PM:10338375

[4] Griffiths, A. M. (2004): Specificities of inflammatory bowel disease in childhood, Best.Pract.Res.Clin.Gastroenterol. 18 [3], Seite 509-523. URL: PM:15157824

[5] Russell, R. K. und Satsangi, J. (2004): IBD: a family affair, Best.Pract.Res.Clin.Gastroenterol. 18 [3], Seite 525-539. URL: PM:15157825

[6] Blumberg, R. S. und Strober, W. (2001): Prospects for research in inflammatory bowel disease, JAMA 285 [5], Seite 643-647. URL: PM:11176874

[7] Podolsky, D. K. (2002): Inflammatory bowel disease, N.Engl.J.Med. 347 [6], Seite 417-429. URL: PM:12167685

[8] Hugot, J. P. (2004): Genetic origin of IBD, Inflamm.Bowel.Dis. 10 Suppl 1, Seite S11-S15. URL: PM:15168824

[9] Yamaguchi, T.; Ihara, K.; Matsumoto, T.; Tsutsumi, Y.; Nomura, A.; Ohga, S. und Hara, T. (2001): Inflammatory bowel disease-like colitis in glycogen storage disease type 1b, Inflamm.Bowel Dis. 7 [2], Seite 128-132. URL: PM:11383585

[10] Hsieh, K. H.; Chang, M. H.; Lee, C. Y. und Wang, C. Y. (1988): Wiskott-Aldrich syndrome and inflammatory bowel disease, Ann.Allergy 60 [5], Seite 429-431. URL: PM:3369753

[11] Binder, V. und Orholm, M. (1996): Familial occurrence and inheritance studies in inflammatory bowel disease, Neth.J.Med. 48 [2], Seite 53-56. URL: PM:8819799

[12] Kurata, J. H.; Kantor-Fish, S.; Frankl, H.; Godby, P. und Vadheim, C. M. (1992): Crohn's disease among ethnic groups in a large health maintenance organization, Gastroenterology 102 [6], Seite 1940-1948. URL: PM:1587413

[13] Monsen, U. (1990): Inflammatory bowel disease. An epidemiological and genetic study, Acta Chir Scand.Suppl 559, Seite 1-42. URL: PM:2092567

[14] Monsen, U.; Bernell, O.; Johansson, C. und Hellers, G. (1991): Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease, Scand.J.Gastroenterol. 26 [3], Seite 302-306. URL: PM:1853152

[15] Tysk, C.; Lindberg, E.; Jarnerot, G. und Floderus-Myrhed, B. (1988): Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking, Gut 29 [7], Seite 990-996. URL: PM:3396969

[16] Cavanaugh, J. A. (2003): IBD International Genetics Consortium: international cooperation making sense of complex disease, Inflamm.Bowel.Dis. 9 [3], Seite 190-193. URL: PM:12792225

[17] Orholm, M.; Binder, V.; Sorensen, T. I.; Rasmussen, L. P. und Kyvik, K. O. (2000): Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study, Scand.J.Gastroenterol. 35 [10], Seite 1075-1081. URL: PM:11099061

[18] Blanchard, J. F.; Bernstein, C. N.; Wajda, A. und Rawsthorne, P. (2001): Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis, Am.J.Epidemiol. 154 [4], Seite 328-335. URL: PM:11495856

[19] Boyko, E. J.; Koepsell, T. D.; Perera, D. R. und Inui, T. S. (1987): Risk of ulcerative colitis among former and current cigarette smokers, N.Engl.J.Med. 316 [12], Seite 707-710. URL: PM:3821808

[20] Calkins, B. M. (1989): A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases & Sciences 34 [12], Seite 1841-1854. URL: PM:2598752

[21] Ekbom, A.; Helmick, C.; Zack, M. und Adami, H. O. (1991): The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden, Gastroenterology 100 [2], Seite 350-358. URL: PM:1985033

[22] Gilat, T. und Rozen, P. (1979): Epidemiology of Crohn's disease and ulcerative colitis: etiologic implications, Isr.J.Med.Sci. 15 [4], Seite 305-308. URL: PM:447495

[23] Kildebo, S.; Breckan, R.; Nordgaard, K.; Burhol, P. G. und Jorde, R. (1989): The incidence of Crohn's disease in northern Norway from 1983 to 1986. Northern Norway Gastroenterology Society, Scand.J.Gastroenterol. 24 [10], Seite 1265-1270. URL: PM:2690317

[24] Kyle, J. (1992): Crohn's disease in the northeastern and northern Isles of Scotland: an epidemiological review, Gastroenterology 103 [2], Seite 392-399. URL: PM:1634058

[25] Lashner, B. A.; Shaheen, N. J.; Hanauer, S. B. und Kirschner, B. S. (1993): Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children, Am.J.Gastroenterol. 88 [3], Seite 356-359. URL: PM:8438840

[26] Loftus, E. V., Jr. und Sandborn, W. J. (2002): Epidemiology of inflammatory bowel disease, Gastroenterol.Clin.North Am. 31 [1], Seite 1-20. URL: PM:12122726

[27] Moum, B.; Aadland, E.; Ekbom, A. und Vatn, M. H. (1996): Seasonal variations in the onset of ulcerative colitis, Gut 38 [3], Seite 376-378. URL: PM:8675089

[28] Sandler, R. S. (1998): The incidence of IBD is higher in the North, Inflamm.Bowel.Dis. 4 [2], Seite 175-176. URL: PM:9687225

[29] Sonnenberg, A. (1988): Geographic and temporal variations of sugar and margarine consumption in relation to Crohn's disease, Digestion 41 [3], Seite 161-171. URL: PM:3265683

[30] Kraehenbuhl, J. P. und Corbett, M. (2004): Immunology. Keeping the gut microflora at bay, Science 303 [5664], Seite 1624-1625. URL: PM:15016988

[31] Elson, C. O. (2002): Genes, microbes, and T cells--new therapeutic targets in Crohn's disease, N.Engl.J.Med. 346 [8], Seite 614-616. URL: PM:11856802

[32] Sartor, R. B. (2004): Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics, Gastroenterology 126 [6], Seite 1620-1633. URL: PM:15168372

[33] Strober, W.; Fuss, I. J. und Blumberg, R. S. (2002): The immunology of mucosal models of inflammation, Annu.Rev.Immunol. 20, Seite 495-549. URL: PM:11861611

[34] Mayer, L. und Shao, L. (2004): Therapeutic potential of oral tolerance, Nat.Rev.Immunol. 4 [6], Seite 407-419. URL: PM:15173830

[35] Delves, P. J. und Roitt, I. M. (2000): The immune system. Second of two parts, N.Engl.J.Med. 343 [2], Seite 108-117. URL: PM:10891520

[36] Delves, P. J. und Roitt, I. M. (2000): The immune system. First of two parts, N.Engl.J.Med. 343 [1], Seite 37-49. URL: PM:10882768

[37] Krieg, A. M. (2002): CpG motifs in bacterial DNA and their immune effects, Annu.Rev.Immunol. 20, Seite 709-760. URL: PM:11861616

[38] Hacker, G.; Redecke, V. und Hacker, H. (2002): Activation of the immune system by bacterial CpG-DNA, Immunology 105 [3], Seite 245-251. URL: PM:11918685

[39] Schreiber, S.; Nikolaus, S. und Hampe, J. (1998): Activation of nuclear factor kappa B inflammatory bowel disease, Gut 42 [4], Seite 477-484. URL: PM:9616307

[40] Blumberg, R. S.; Lencer, W. I.; Zhu, X.; Kim, H. S.; Claypool, S.; Balk, S. P.; Saubermann, L. J. und Colgan, S. P. (1999): Antigen presentation by intestinal epithelial cells, Immunol.Lett. 69 [1], Seite 7-11. URL: PM:10436875

[41] Germain, R. N. und Jenkins, M. K. (2004): In vivo antigen presentation, Curr.Opin.Immunol. 16 [1], Seite 120-125. URL: PM:14734120

[42] Hudson, A. W. und Ploegh, H. L. (2002): The cell biology of antigen presentation, Exp.Cell Res. 272 [1], Seite 1-7. URL: PM:11740859

[43] Lauvau, G. und Glaichenhaus, N. (2004): Mini-review: Presentation of pathogen-derived antigens in vivo, Eur.J.Immunol. 34 [4], Seite 913-920. URL: PM:15048701

[44] Mitchison, N. A. (2004): T-cell-B-cell cooperation, Nat.Rev.Immunol. 4 [4], Seite 308-312. URL: PM:15057789

[45] Powrie, F. und Maloy, K. J. (2003): Immunology. Regulating the regulators, Science 299 [5609], Seite 1030-1031. URL: PM:12586934

[46] Shortman, K. und Heath, W. R. (2001): Immunity or tolerance? That is the question for dendritic cells, Nat.Immunol. 2 [11], Seite 988-989. URL: PM:11685217

[47] Wittig, B. M. und Zeitz, M. (2003): The gut as an organ of immunology, Int.J.Colorectal Dis. 18 [3], Seite 181-187. URL: PM:12673481

[48] Mowat, A. M.; Millington, O. R. und Chirdo, F. G. (2004): Anatomical and cellular basis of immunity and tolerance in the intestine, J.Pediatr.Gastroenterol.Nutr. 39 Suppl 3, Seite S723-S724. URL: PM:15167360

[49] Hao, W. L. und Lee, Y. K. (2004): Microflora of the gastrointestinal tract: a review, Methods Mol.Biol. 268, Seite 491-502. URL: PM:15156063

[50] Garside, P. und Mowat, A. M. (2001): Oral tolerance, Semin.Immunol. 13 [3], Seite 177-185. URL: PM:11394960

[51] Baumgart, D. C. und Dignass, A. U. (2002): Intestinal barrier function, Curr.Opin.Clin.Nutr.Metab Care 5 [6], Seite 685-694. URL: PM:12394645

[52] Shanahan, F. (2004): Host-flora interactions in inflammatory bowel disease, Inflamm.Bowel Dis. 10 Suppl 1, Seite S16-S24. URL: PM:15168825

[53] MacDonald, T. T. und Spencer, J. (1988): Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine, J.Exp.Med. 167 [4], Seite 1341-1349. URL: PM:2965735

[54] Evans, C. M.; Phillips, A. D.; Walker-Smith, J. A. und MacDonald, T. T. (1992): Activation of lamina propria T cells induces crypt epithelial proliferation and goblet cell depletion in cultured human fetal colon, Gut 33 [2], Seite 230-235. URL: PM:1541419

[55] Blumberg, R. S.; Saubermann, L. J. und Strober, W. (1999): Animal models of mucosal inflammation and their relation to human inflammatory bowel disease, Curr.Opin.Immunol. 11 [6], Seite 648-656. URL: PM:10631550

[56] Sadlack, B.; Merz, H.; Schorle, H.; Schimpl, A.; Feller, A. C. und Horak, I. (1993): Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene [see comments], Cell 75 [2], Seite 253-261.

[57] Ma, A.; Datta, M.; Margosian, E.; Chen, J. und Horak, I. (1995): T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice, J Exp Med 182 [5], Seite 1567-1572.

[58] Baumgart, D. C.; Rombeau, J. L. und Carding, S. R. (1997): Mechanisms of tissue injury in ulcerative colitis like disease in interleukin-2 deficient mice, Gastroenterology 112 [4], Seite A929-A929. URL: ISI:A1997WV41903703

[59] Baumgart, D. C.; McVay, L. D. und Carding, S. R. (1998): Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review), Int.J.Mol.Med. 1 [2], Seite 315-332. URL: PM:9852233

[60] Baumgart, D. C.; Olivier, W. A.; Reya, T.; Peritt, D.; Rombeau, J. L. und Carding, S. R. (1998): Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice, Cell Immunol. 187 [1], Seite 52-66. URL: PM:9682004

[61] Contractor, N. V.; Bassiri, H.; Reya, T.; Park, A. Y.; Baumgart, D. C.; Wasik, M. A.; Emerson, S. G. und Carding, S. R. (1998): Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice, J.Immunol. 160 [1], Seite 385-394. URL: PM:9551995

[62] Baumgart, D. C.; Rombeau, J. L. und Carding, S. R. (1998): Antigen presentation capabilities of primary murine colonic epithelial cells, Gastroenterology 114 [4], Seite A928-A928. URL: ISI:000073089603779

[63] Blumberg, R. S. (1998): Current concepts in mucosal immunity. II. One size fits all: nonclassical MHC molecules fulfill multiple roles in epithelial cell function, Am.J.Physiol 274 [2 Pt 1], Seite G227-G231. URL: PM:9486173

[64] Macartney, K. K.; Baumgart, D. C.; Carding, S. R.; Brubaker, J. O. und Offit, P. A. (2000): Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection, J.Virol. 74 [12], Seite 5597-5603. URL: PM:10823867

[65] Telega, G. W.; Baumgart, D. C. und Carding, S. R. (2000): Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states, Gastroenterology 119 [6], Seite 1548-1559. URL: PM:11113076

[66] Mellman, I. und Steinman, R. M. (2001): Dendritic cells: specialized and regulated antigen processing machines, Cell 106 [3], Seite 255-258. URL: PM:11509172

[67] Iwasaki, A. und Kelsall, B. L. (1999): Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses, Am.J.Physiol 276 [5 Pt 1], Seite G1074-G1078. URL: PM:10329996

[68] Dhodapkar, M. V.; Steinman, R. M.; Krasovsky, J.; Munz, C. und Bhardwaj, N. (2001): Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells, J Exp.Med 193 [2], Seite 233-238. URL: PM:11208863

[69] Hawiger, D.; Inaba, K.; Dorsett, Y.; Guo, M.; Mahnke, K.; Rivera, M.; Ravetch, J. V.; Steinman, R. M. und Nussenzweig, M. C. (2001): Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo, J Exp.Med 194 [6], Seite 769-779. URL: PM:11560993

[70] Steinman, R. M. und Nussenzweig, M. C. (2002): Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance, Proc.Natl.Acad.Sci.U.S.A 99 [1], Seite 351-358. URL: PM:11773639

[71] Jonuleit, H.; Schmitt, E.; Schuler, G.; Knop, J. und Enk, A. H. (2000): Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells, J.Exp.Med. 192 [9], Seite 1213-1222. URL: PM:11067871

[72] Roncarolo, M. G.; Levings, M. K. und Traversari, C. (2001): Differentiation of T regulatory cells by immature dendritic cells, J.Exp.Med. 193 [2], Seite F5-F9. URL: PM:11208869

[73] Schwartz, R. H. (2003): T cell anergy, Annu.Rev.Immunol. 21, Seite 305-334. URL: PM:12471050

[74] Viney, J. L.; Mowat, A. M.; O'Malley, J. M.; Williamson, E. und Fanger, N. A. (1998): Expanding dendritic cells in vivo enhances the induction of oral tolerance, J.Immunol. 160 [12], Seite 5815-5825. URL: PM:9637492

[75] Bell, S. J.; Rigby, R.; English, N.; Mann, S. D.; Knight, S. C.; Kamm, M. A. und Stagg, A. J. (2001): Migration and maturation of human colonic dendritic cells, J.Immunol. 166 [8], Seite 4958-4967. URL: PM:11290774

[76] Dhodapkar, M. V.; Steinman, R. M.; Sapp, M.; Desai, H.; Fossella, C.; Krasovsky, J.; Donahoe, S. M.; Dunbar, P. R.; Cerundolo, V.; Nixon, D. F. und Bhardwaj, N. (1999): Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells, J Clin.Invest 104 [2], Seite 173-180. URL: PM:10411546

[77] Stagg, A. J.; Hart, A. L.; Knight, S. C. und Kamm, M. A. (2003): The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria, Gut 52 [10], Seite 1522-1529. URL: PM:12970149

[78] Iwasaki, A. und Kelsall, B. L. (1999): Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells, J.Exp.Med. 190 [2], Seite 229-239. URL: PM:10432286

[79] Singh, B.; Read, S.; Asseman, C.; Malmstrom, V.; Mottet, C.; Stephens, L. A.; Stepankova, R.; Tlaskalova, H. und Powrie, F. (2001): Control of intestinal inflammation by regulatory T cells, Immunol.Rev. 182, Seite 190-200. URL: PM:11722634

[80] Malmstrom, V.; Shipton, D.; Singh, B.; Al-Shamkhani, A.; Puklavec, M. J.; Barclay, A. N. und Powrie, F. (2001): CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice, J.Immunol. 166 [11], Seite 6972-6981. URL: PM:11359859

[81] Ashcroft, A. J.; Cruickshank, S. M.; Croucher, P. I.; Perry, M. J.; Rollinson, S.; Lippitt, J. M.; Child, J. A.; Dunstan, C.; Felsburg, P. J.; Morgan, G. J. und Carding, S. R. (2003): Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin, Immunity. 19 [6], Seite 849-861. URL: PM:14670302

[82] Krieg, A. M. (2003): CpG motifs: the active ingredient in bacterial extracts?, Nat.Med. 9 [7], Seite 831-835. URL: PM:12835699

[83] Baumgart, D. C.; Metzke, D.; Schmitz, J.; Scheffold, A.; Sturm, A.; Wiedenmann, B. und Dignass, A. U. (2004): Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid (PDC) and myeloid (MDC) dendritic cells., Gut.

[84] Sandborn, W. J. (2001): Cyclosporine in ulcerative colitis: state of the art, Acta Gastroenterol.Belg. 64 [2], Seite 201-204. URL: PM:11475136

[85] Hanauer, S. B. und Dassopoulos, T. (2001): Evolving treatment strategies for inflammatory bowel disease, Annu.Rev.Med. 52, Seite 299-318. URL: PM:11160781

[86] Marsh, J. W.; Vehe, K. L. und White, H. M. (1992): Immunosuppressants, Gastroenterol.Clin.North Am. 21 [3], Seite 679-693. URL: PM:1516962

[87] Latteri, M.; Angeloni, T. G.; Silveri, N. G.; Manna, R.; Gasbarrini, G. und Navarra, P. (2001): Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease, Clin.Pharmacokinet. 40 [6], Seite 473-483. URL: PM:11475470

[88] Navazo, L.; Salata, H.; Morales, S.; Dorta, M. C.; Perez, F.; de las, Casas D. und Aviles, J. (2001): Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis, Scand.J.Gastroenterol. 36 [6], Seite 610-614. URL: PM:11424319

[89] Goto, T.; Kino, T.; Hatanaka, H.; Nishiyama, M.; Okuhara, M.; Kohsaka, M.; Aoki, H. und Imanaka, H. (1987): Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis, Transplant.Proc. 19 [5 Suppl 6], Seite 4-8. URL: PM:2445072

[90] Kino, T.; Hatanaka, H.; Miyata, S.; Inamura, N.; Nishiyama, M.; Yajima, T.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H. und . (1987): FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J.Antibiot.(Tokyo) 40 [9], Seite 1256-1265. URL: PM:2445722

[91] Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H. und Imanaka, H. (1987): FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics, J.Antibiot.(Tokyo) 40 [9], Seite 1249-1255. URL: PM:2445721

[92] Carballo, M.; Marquez, G.; Conde, M.; Martin-Nieto, J.; Monteseirin, J.; Conde, J.; Pintado, E. und Sobrino, F. (1999): Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-kappaB DNA binding, J.Biol.Chem. 274 [1], Seite 93-100. URL: PM:9867815

[93] Furuke, K.; Shiraishi, M.; Mostowski, H. S. und Bloom, E. T. (1999): Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway, J.Immunol. 162 [4], Seite 1988-1993. URL: PM:9973469

[94] Aiko, S.; Conner, E. M.; Fuseler, J. A. und Grisham, M. B. (1997): Effects of cyclosporine or FK506 in chronic colitis, J.Pharmacol.Exp.Ther. 280 [2], Seite 1075-1084. URL: PM:9023326

[95] Takizawa, H.; Shintani, N.; Natsui, M.; Sasakawa, T.; Nakakubo, H.; Nakajima, T. und Asakura, H. (1995): Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506, Digestion 56 [3], Seite 259-264. URL: PM:7544748

[96] Higa, A.; McKnight, G. W. und Wallace, J. L. (1993): Attenuation of epithelial injury in acute experimental colitis by immunomodulators, Eur.J.Pharmacol. 239 [1-3], Seite 171-176. URL: PM:7693488

[97] Hoshino, H.; Goto, H.; Sugiyama, S.; Hayakawa, T. und Ozawa, T. (1995): Effects of FK506 on an experimental model of colitis in rats, Aliment.Pharmacol.Ther. 9 [3], Seite 301-307. URL: PM:7544633

[98] Bousvaros, A.; Kirschner, B. S.; Werlin, S. L.; Parker-Hartigan, L.; Daum, F.; Freeman, K. B.; Balint, J. P.; Day, A. S.; Griffiths, A. M.; Zurakowski, D.; Ferry, G. D. und Leichtner, A. M. (2000): Oral tacrolimus treatment of severe colitis in children, J.Pediatr. 137 [6], Seite 794-799. URL: PM:11113835

[99] Bousvaros, A.; Wang, A. und Leichtner, A. M. (1996): Tacrolimus (FK-506) treatment of fulminant colitis in a child, J.Pediatr.Gastroenterol.Nutr. 23 [3], Seite 329-333. URL: PM:8890089

[100] Lowry, P. W.; Weaver, A. L.; Tremaine, W. J. und Sandborn, W. J. (1999): Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae, Inflamm.Bowel.Dis. 5 [4], Seite 239-245. URL: PM:10579116

[101] Matsuhashi, N.; Nakajima, A.; Watanabe, K.; Komeno, Y.; Suzuki, A.; Ohnishi, S.; Omata, M.; Kondo, K.; Usui, Y.; Iwadare, J. I.; Watanabe, T.; Nagawa, H. und Muto, T. (2000): Tacrolimus in corticosteroid-resistant ulcerative colitis, J.Gastroenterol. 35 [8], Seite 635-640. URL: PM:10955604

[102] Sandborn, W. J.; Present, D. H.; Isaacs, K. L.; Wolf, D. C.; Greenberg, E.; Hanauer, S. B.; Feagan, B. G.; Johnson, T.; Joseph, G.; Martin, C. F. und Sandler, R. S. (2002): Tacrolimus (FK506) for the treatment of perianal and enterocutaneous fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled trial, Gastroenterology 122 [4], Seite 670. URL: ISI:000175366600405

[103] Fellermann, K.; Ludwig, D.; Stahl, M.; David-Walek, T. und Stange, E. F. (1998): Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506), American Journal of Gastroenterology 93 [10], Seite 1860-1866. URL: ISI:000076315900014

[104] Targan, S. R.; Hanauer, S. B.; van Deventer, S. J.; Mayer, L.; Present, D. H.; Braakman, T.; DeWoody, K. L.; Schaible, T. F. und Rutgeerts, P. J. (1997): A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N.Engl.J.Med. 337 [15], Seite 1029-1035. URL: PM:9321530

[105] Baumgart, D. C.; Wiedenmann, B. und Dignass, A. U. (2003): Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease, Aliment.Pharmacol.Ther. 17 [10], Seite 1273-1281. URL: PM:12755840

[106] Baumgart, D. C.; Wiedenmann, B. und Dignass, A. U. (2004): Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis, Inflammatory Bowel Diseases 10 [4], Seite 421-424. URL: ISI:000222479900013

[107] Baumgart, D. C. und Dignass, A. U. (2004): Current biological therapies in inflammatory bowel disease., Curr.Pharm.Design..

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: